Taxane-resistant lymphoepithelial-like carcinoma: excellent response to VIP chemotherapy

Ir J Med Sci. 2006 Jul-Sep;175(3):64-5. doi: 10.1007/BF03169176.

Abstract

Background: Lymphoepithelial-like carcinoma is a rare tumour type. The optimal treatment for this disease is not known. No effective therapies are described in the literature.

Aims: This report describes a case of lymphoepithelial-like carcinoma and documents a therapeutic strategy which has proved effective.

Results: The patient was initially treated with a common platinum-based chemotherapy regimen incorporating a taxane (Carbplatin and Docetaxel). Disease stabilization initially occurred but the patient soon progressed. The patient was then treated with VIP chemotherapy and had a complete response.

Conclusion: VIP chemotherapy appears to be an effective therapeutic strategy in lymphoepithelial-like carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bridged-Ring Compounds / therapeutic use*
  • Carcinoma / diagnostic imaging
  • Carcinoma / drug therapy*
  • Cisplatin / therapeutic use
  • Drug Resistance, Neoplasm*
  • Humans
  • Ifosfamide / therapeutic use
  • Male
  • Muscle Neoplasms / diagnostic imaging
  • Muscle Neoplasms / drug therapy*
  • Podophyllotoxin / therapeutic use
  • Psoas Muscles*
  • Radiography
  • Taxoids / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Bridged-Ring Compounds
  • Taxoids
  • taxane
  • Podophyllotoxin
  • Cisplatin
  • Ifosfamide

Supplementary concepts

  • VIP protocol 2